Anbio Biotechnology Outperforms Oncocyte in Financial Metrics

Comparison of key financial and operational indicators between the two biotech manufacturers

Feb. 27, 2026 at 10:38am

Got story updates? Submit your updates here. ›

Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN) are both manufacturing companies in the biotech industry, but an analysis shows that Anbio Biotechnology outperforms Oncocyte on several key financial and operational metrics, including higher revenue, earnings, and a more favorable analyst consensus.

Why it matters

This comparison is relevant for investors looking to evaluate the relative performance and growth potential of these two biotech firms. The findings could impact investment decisions and market sentiment around the companies.

The details

The analysis found that Anbio Biotechnology has higher revenue and earnings per share compared to Oncocyte. Anbio also received more favorable ratings and a higher price target from equity research analysts. Additionally, Anbio has stronger institutional ownership, which is seen as an indicator of the company's long-term growth prospects.

  • The financial data is based on the most recent fiscal year and six-month period ended June 30, 2024.

The players

Oncocyte Corporation

A molecular diagnostics company that researches, develops, and commercializes proprietary laboratory-developed tests for cancer detection.

Anbio Biotechnology

A company dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products, with a focus on transforming the diagnostics landscape through personalized and decentralized solutions.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the relative strengths of Anbio Biotechnology compared to Oncocyte, with Anbio demonstrating superior financial performance and a more favorable market outlook. Investors evaluating these two biotech firms should consider these findings as part of their due diligence process.